TICKERNERD
Menu
PRAXPRAXHealthcare · Biotechnology

PRAX Stock Forecast: Praxis Precision Medicines, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$355
−0.76% on the day

The 19 Wall Street analysts covering Praxis Precision Medicines, Inc. hold a median 12-month price target of $575 — +62.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 2 Sept 2026 — in the lower half.

Market cap
$9.9B
Ticker Nerd rank
44 / 100
Median analyst target
$575
Analysts covering
19
Revenue$0.0
Operating income−$105.9M
Net income−$92.6M
Free cash flow−$86.2M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.6%
1M
+16.1%
YTD
+20.4%
1Y
+662.1%
From 52W high
−8.2%
From 52W low
+840.9%
$38
$386
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRAX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Praxis Precision Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
44 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
93
Value
75
Revisions
69
Quality
65
Growth
36
Accruals
27
Issuance
26
Volatility
19
Size
16

Momentum (93): The shares have been drifting up relative to others.

Volatility (19): The share price moves around a lot.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PRAX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRAX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$200$400$600$800$1,000$1,200Oct 25Jan 26Apr 26Jul 26PRAXHigh $1,201Median $575Low $188

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
17 Buy1 Hold1 Sell
Low $188Median $575High $1,201

The green dot is the last close — the median target sits +62.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
21 Aug 2026Goldman SachsMaintainsBuy$470 → $575
7 Aug 2026RBC CapitalMaintainsOutperform$449 → $462
7 Aug 2026RBC CapitalMaintainsOutperform—
7 Aug 2026Wells FargoMaintainsEqual-Weight$323 → $362
7 Aug 2026Wells FargoMaintainsEqual-Weight—
6 Aug 2026NeedhamMaintainsBuy—
6 Aug 2026NeedhamMaintainsBuy$575 → $582
29 July 2026BTIGReiteratesBuy$810
29 July 2026BTIGReiteratesBuy—
13 July 2026Goldman SachsInitiatesBuy—
13 July 2026Goldman SachsInitiatesBuy$447
29 June 2026NeedhamMaintainsBuy—
18 June 2026RBC CapitalInitiatesOutperform—
2 June 2026BairdMaintainsOutperform—
2 June 2026BTIGMaintainsBuy—
2 June 2026Deutsche BankMaintainsBuy—
2 June 2026HC Wainwright & Co.MaintainsBuy—
2 June 2026OppenheimerMaintainsOutperform—
2 June 2026Truist SecuritiesMaintainsBuy—
2 June 2026WedbushMaintainsUnderperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRAX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PRAX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Praxis Precision Medicines, Inc. returned +662.1% against +21.4% for the S&P 500, dividends included.

PRAX vs S&P 500, last 12 monthsTotal return, rebased to 100
0200400600800Oct 25Jan 26Apr 26Jul 26PRAXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PRAX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Praxis Precision Medicines, Inc. (PRAX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−26.2×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
7.4×

Cheaper than 14% of US stocks

EV / EBITDA
−23.5×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−38.9%

Higher than 24% of US stocks

Return on assets
−25.7%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Praxis Precision Medicines, Inc. (PRAX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Praxis Precision Medicines, Inc. has a market value of $9.9B and an enterprise value of $8.9B.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$326.5M.

  • Diluted earnings per share, trailing twelve months: $−13.37.

  • Free cash flow in the twelve months to 31 Mar 2026: −$282.3M, after $118K of capital spending.

  • Shares outstanding: 27.9M.

  • Trailing P/E: −26.2×; forward P/E: −38.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Praxis Precision Medicines, Inc. employs 168 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 2 Sept 2026

Data provided by Twelve Data

Peers

PRAX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PRAXPraxis Precision Medicines, Inc.$9.9B
44
IONSIonis Pharmaceuticals, Inc.$9.8B
48
KYMRKymera Therapeutics, Inc.$9.9B
73
CYTKCytokinetics, Inc.$10.0B
47
APGEApogee Therapeutics, Inc.$10.2B
35
PTGXProtagonist Therapeutics, Inc.$9.3B
97
TGTXTG Therapeutics, Inc.$9.0B
68

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Praxis Precision Medicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRAX news & analysis

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 3 Sept 2026neutral

Praxis Precision Medicines announced that on September 1, 2026, its Compensation Committee granted restricted stock unit awards covering an aggregate of 11,535 shares of common stock to sixty-six new non-executive employees under the company's 2024 Inducement Plan. The awards were granted as inducements material to the employees joining Praxis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — The grants signal continued hiring and share-based compensation for new employees, which PRAX watchers would track for potential dilution and workforce growth.

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Zacks Investment Research · 11 Aug 2026neutral

Zacks Investment Research highlighted Praxis Precision Medicines as one of four biotech stocks with major second-half pipeline catalysts this year, including potential FDA decisions and late-stage data readouts.

Why it matters — PRAX watchers would care because the article points to upcoming pipeline events and regulatory catalysts for the company in the latter part of the year.

Praxis: Commercial Launch Could Smash Expectations (Video)

Seeking Alpha · 7 Aug 2026positive

A Seeking Alpha video analyzes Praxis Precision Medicines using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. It highlights updates from a Goldman Sachs presentation on key developments and upcoming catalysts ahead of Ulixa's commercial launch, assessing PRAX's strategic positioning around the product's market entry.

Why it matters — PRAX watchers would care because the analysis centers on Ulixa's commercial launch and the upcoming catalysts tied to entering the market.

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Praxis Precision Medicines, Inc. (PRAX) held its Q2 2026 earnings call, and the transcript was published by Seeking Alpha. The item announces the availability of the company's second-quarter 2026 earnings discussion.

Why it matters — A PRAX watcher would care because the transcript provides a record of management's commentary on the company's Q2 2026 financial results and business developments.

Praxis Precision Medicines Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

Praxis Precision Medicines reported that it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related DEEs while both NDAs remain under FDA review.

Why it matters — A PRAX watcher would care because the company is moving toward commercialization of two pipeline candidates, signaling potential near-term revenue opportunities if FDA approvals are granted.

FAQ

Frequently asked questions about PRAX stock

What is the PRAX stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Praxis Precision Medicines, Inc. have a median 12-month price target of $575, with estimates ranging from $188 to $1,201. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PRAX stock a buy right now?

Of the 19 analysts covering Praxis Precision Medicines, Inc., 17 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Praxis Precision Medicines, Inc. 44 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRAX?

As at 2 Sept 2026, Praxis Precision Medicines, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).

Will PRAX stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +62.1% from the last close, and Ticker Nerd's factor model ranks Praxis Precision Medicines, Inc. 44 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PRAX stock forecast for 2030?

No analyst covering Praxis Precision Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $188 to $1,201 over the next 12 months.

How has PRAX stock performed over the past year?

Praxis Precision Medicines, Inc. returned +662.1% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Praxis Precision Medicines, Inc. do?

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders characterized by neuronal excitability and excitation-inhibition imbalance.

What is the latest news on PRAX?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Praxis Precision Medicines announced that on September 1, 2026, its Compensation Committee granted restricted stock unit awards covering an aggregate of 11,535 shares of common stock to sixty-six new non-executive employees under the company's 2024 Inducement Plan. The awards were granted as inducements material to the employees joining Praxis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders characterized by neuronal excitability and excitation-inhibition imbalance. Praxis Precision Medicines, Inc. applies genetic and translational neuroscience insights to create treatments for movement disorders, epilepsy, and selected psychiatric and neurological conditions. Its portfolio includes both small-molecule programs and antisense oligonucleotide therapies, supported by proprietary research platforms designed to match drug candidates to specific biological targets and patient subgroups. The company’s work centers on disorders where shared neural circuitry and genetic mechanisms may help guide more targeted therapeutic development. Praxis Precision Medicines, Inc. operates as a research-driven biotech organization with a pipeline that spans multiple CNS indications and reflects a precision medicine approach to brain health.

CEO Mr. Marcio Silva De'Souza M.B.A. · 168 employees · United States · https://praxismedicines.com